Randomized clinical trial demonstrates significant improvements in walking ability for patients receiving therapy with the ReStore Exo-Suit as compared to a matched control group receiving ...
Additional progress with traditional Medicare claim approvals has accelerated timelines to payment in 2025 MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd ...
MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILLIT, Israel, Nov. 30, 2023 (GLOBE NEWSWIRE) -- ReWalk Robotics, Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company"), a leading provider of innovative ...
MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILLIT, Israel, Jan. 05, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk”), a leading provider of innovative technologies that enable ...
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 13, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to ...
“Nationally nearly half of all Medicare Advantage enrollees are now eligible for prior authorization and reimbursement for ReWalk 7,” said Mark Grant, CEO of Lifeward. “This prior authorization ...
Distribution agreement with Singapore-based Verita Neuro will provide patients the ReWalk Personal Exoskeleton as part of its multi-layered treatment modalities New delivery model for ReWalk will ...
The Lifeward portfolio features innovative products including the ReWalk Exoskeleton, the AlterG Anti-Gravity System, the ReStore Exo-Suit, and the MyoCycle FES System. Founded in 2001, Lifeward has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback